{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T05:30:29Z","timestamp":1772775029725,"version":"3.50.1"},"reference-count":122,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1517\/13543784.13.4.373","type":"journal-article","created":{"date-parts":[[2005,5,4]],"date-time":"2005-05-04T17:27:20Z","timestamp":1115227640000},"page":"373-391","source":"Crossref","is-referenced-by-count":14,"title":["Recent developments in the pharmacological treatment of Crohn\u2019s disease"],"prefix":"10.1517","volume":"13","author":[{"given":"Radhika","family":"Srinivasan","sequence":"first","affiliation":[{"name":"Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Gastroenterology Division, 3rd Floor Ravdin Building, 3400 Spruce Street, Philadelphia, PA 19104-4283, USA. grl@uphs.upenn.edu"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary R","family":"Lichtenstein","sequence":"additional","affiliation":[{"name":"Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Gastroenterology Division, 3rd Floor Ravdin Building, 3400 Spruce Street, Philadelphia, PA 19104-4283, USA. grl@uphs.upenn.edu"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2005,3,2]]},"reference":[{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1932.02740680019005"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(76)80163-1"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)92767-1"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(89)80080-0"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(95)90277-5"},{"key":"e_1_2_1_8_1","doi-asserted-by":"crossref","unstructured":"TARGAN SR HANAUER SB VAN DEVENTER SJ et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. New Engl. J. Med. (1997) 337:1029\u20131035.","DOI":"10.1056\/NEJM199710093371502"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199905063401804"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70332-X"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.24042"},{"key":"e_1_2_1_13_1","doi-asserted-by":"crossref","unstructured":"FEAGAN BG SANDBORN WJ BAKER JP et al.: A randomized double-blind placebo controlled multi-center trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease. Proceedings of the Digestive Disease Week San Diego USA (2000):A655.","DOI":"10.1016\/S0016-5085(00)84761-7"},{"key":"e_1_2_1_14_1","doi-asserted-by":"crossref","unstructured":"SANDBORN WJ FEAGAN B RADFORD-SMITH G KOVACS A ENNS R PATEL J: A randomized placebo-controlled trial of CDP571 a humanized monoclonal antibody to TNF-a in patients with moderate to severe Crohn's disease. Proceedings of the Digestive Disease Week Orlando USA (2003):A469.","DOI":"10.1016\/S0016-5085(03)80302-5"},{"key":"e_1_2_1_15_1","doi-asserted-by":"crossref","unstructured":"D'HAENS G SWIJSEN C NORMAN M et al.: Etanercept (TNF receptor fusion protein Enbrel) is effective and well tolerated in active refractory Crohn's disease: results of a single center pilot trial. Proceedings of the Digestive Disease Week Atlanta USA (2001):A656.","DOI":"10.1016\/S0016-5085(00)84762-9"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.28674"},{"key":"e_1_2_1_17_1","unstructured":"\u2022\u2022This study showed that etanercept at 25mg twice-weekly had no benefit in CD."},{"key":"e_1_2_1_18_1","doi-asserted-by":"crossref","unstructured":"RUTGEERTS P LEMMENS L GERT VAN ASSCHE et al.: Recombinant soluble p55 TNF receptor induces remission is non immunogenic and well tolerated in active Crohn's disease: results of a randomized pilot trial. Proceedings of the Digestive Disease Week Atlanta USA (2001):A2304.","DOI":"10.1016\/S0016-5085(08)82243-3"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01414.x"},{"key":"e_1_2_1_20_1","unstructured":"\u2022A pilot study that has shown treatment benefit of onercept in CD."},{"issue":"2","key":"e_1_2_1_21_1","first-page":"351","article-title":"Adalimumab - a new TNF-alpha antibody for treatment of inflammatory joint disease","volume":"3","author":"MacHOLD KP","year":"2003","unstructured":"MacHOLD KP, SMOLEN JS: Adalimumab - a new TNF-alpha antibody for treatment of inflammatory joint disease. Expert Opin. Investig. Drugs (2003) 3(2):351\u2013360.","journal-title":"Expert Opin. Investig. Drugs"},{"key":"e_1_2_1_22_1","doi-asserted-by":"crossref","unstructured":"SCHREIBER S RUTGEERTS P FED ORAK R KHALIQ-KAREEMI M KAMM MA PATEL J: CDP 870 a humanized anti-TNF antibody fragment induces clinical response with remission in patients with active Crohn's disease. Proceedings of the Digestive Disease Week Orlando USA (2003):A468.","DOI":"10.1016\/S0016-5085(03)80301-3"},{"key":"e_1_2_1_23_1","doi-asserted-by":"crossref","unstructured":"SCHREIBER S WINTER T INNES A PATEL J: Safety of CDP870 a pegylated humanized anti-TNF antibody fragment in Crohn's disease. Proceedings of the American College of Gastroenterology Annual Meeting Baltimore USA (2003):A300.","DOI":"10.1111\/j.1572-0241.2003.08480.x"},{"key":"e_1_2_1_24_1","doi-asserted-by":"crossref","unstructured":"SCHREIBER S RUTGEERTS P INNES A PATEL J: CDP870 a pegylated humanized anti-TNF antibody fragment offers particular benefit to Crohn's disease patients with elevated C-reactive protein. Proceedings of the American College of Gastroenterology Annual Meeting. Baltimore USA (2003):A299.","DOI":"10.1111\/j.1572-0241.2003.08479.x"},{"key":"e_1_2_1_25_1","unstructured":"\u2022Has shown that CD patients with elevated levels of CRP may be a different subgroup in terms of treatment response to anti-TNF therapy."},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70299-4"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70276-3"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70277-5"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005176-200102000-00016"},{"key":"e_1_2_1_30_1","doi-asserted-by":"crossref","unstructured":"BAUDITZ J WEDEL S LOCHS H: Thalidomide reduces tumor necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut (2002) 50(2):196\u2013200.","DOI":"10.1136\/gut.50.2.196"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1999.01039.x"},{"issue":"8","key":"e_1_2_1_32_1","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.4049\/jimmunol.161.8.4236","article-title":"CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production","volume":"161","author":"MARRIOT JB","year":"1998","unstructured":"MARRIOT JB, WESTBY M, COOKSON S et al.: CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production. I Immunol. (1998) 161(8):4236\u20134243.","journal-title":"I Immunol."},{"key":"e_1_2_1_33_1","unstructured":"\u2022Paved the way for use of thalidomide analogues that have fewer side effects than thalidomide in inflammatory diseases like arthritis and CD."},{"key":"e_1_2_1_34_1","unstructured":"BARLOGIE B: Pilot Phase I\/II trial of CCHH-1088 versus placebo in Crohn's disease. Proceedings of the SMA Anti-Arthritic Agents Meeting London UK (2003)."},{"key":"e_1_2_1_35_1","doi-asserted-by":"crossref","unstructured":"HOMMES D VAN DER BLINK B PLASSE T et al.: Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology (2002) 122(1):7\u201314.","DOI":"10.1053\/gast.2002.30770"},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.11.7.947"},{"key":"e_1_2_1_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.40.4.470"},{"key":"e_1_2_1_38_1","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/S0022-3565(24)29455-6","article-title":"Inhibition of tumor necrosis factor-alpha production and arthritis in the rat by GW3333, a dual inhibitor of TNF-alpha converting enzyme and matrix metalloproteinases","volume":"298","author":"CONWAY JG","year":"2001","unstructured":"CONWAY JG, ANDREWS RC, BEAUDET B et al: Inhibition of tumor necrosis factor-alpha production and arthritis in the rat by GW3333, a dual inhibitor of TNF-alpha converting enzyme and matrix metalloproteinases. .1. Pharmacol. Exp. Ther. (2001) 298:900\u2013908.","journal-title":"1. Pharmacol. Exp. Ther."},{"key":"e_1_2_1_39_1","unstructured":"Preclinical data on doramapimod. Proceedings of the Drug Discovery Technology meeting Boston USA (2002)."},{"key":"e_1_2_1_40_1","doi-asserted-by":"crossref","unstructured":"DUCHMANN R SCHMITT E KNOLLE P et al.: Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Ear: .1. Immunol. (1996) 26:934\u2013938.","DOI":"10.1002\/eji.1830260432"},{"key":"e_1_2_1_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)80068-P"},{"key":"e_1_2_1_42_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1997.v113.pm9247454"},{"key":"e_1_2_1_43_1","doi-asserted-by":"crossref","unstructured":"FEDORAK RN GANGL A ELSON CO et al.: Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology (2000) 119:1473\u20131482.","DOI":"10.1053\/gast.2000.20229"},{"key":"e_1_2_1_44_1","unstructured":"\u2022This study failed to show efficacy of rhIL-10 in treatment of mild-to-moderately active CD."},{"key":"e_1_2_1_45_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2000.20196"},{"key":"e_1_2_1_46_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.3.363"},{"key":"e_1_2_1_47_1","unstructured":"\u2022\u2022This novel approach by using adenoviralvectors to induce murine colonic IL-10 production and thereby restore mucosal immune homeostasis is ground breaking and bodes well for future human studies."},{"key":"e_1_2_1_48_1","first-page":"1865","article-title":"Prevention of colitis by interleukin 10-transducedT lymphocytes in the SCID mice transfer model","volume":"2002","author":"VAN MONTFRANS C","unstructured":"VAN MONTFRANS C, RODRIGUES PENA MS, PRONK I, TEN KATE FJW, TE VELDE AA, VAN DEVENTER SJH: Prevention of colitis by interleukin 10-transducedT lymphocytes in the SCID mice transfer model. Gastroenterology (2002) 123: 1865-1876.","journal-title":"Gastroenterology"},{"key":"e_1_2_1_49_1","doi-asserted-by":"crossref","unstructured":"GREENWOOD-VAN MEERVELD B VENKOVA K KEITH JC Jr: Recombinant human interleukin-11 restores smooth muscle function in the jejunum and colon of human leukocyte antigen-B27 rats with intestinal inflammation. Pharmacol. Exp. The]: (2001) 299:58\u201366.","DOI":"10.1016\/S0022-3565(24)29301-0"},{"key":"e_1_2_1_50_1","unstructured":"KEITH JC Jr ALBERT L SONIS ST et al.: IL-11 a pleiotropic cytokine: exciting new effects of IL-11 on gastrointestinal mucosal biology. Stem Cells (1994) (Suppl. 1):79\u201389."},{"key":"e_1_2_1_51_1","first-page":"1503","article-title":"Molecular effects of recombinant human interleukin-11 in the HLA-B27 rat model of inflammatory bowel disease","volume":"78","author":"PETERSON RL","year":"1998","unstructured":"PETERSON RL, WANG L, ALBERT L et al.: Molecular effects of recombinant human interleukin-11 in the HLA-B27 rat model of inflammatory bowel disease. Lab. Invest. (1998) 78:1503\u20131512.","journal-title":"Lab. Invest."},{"key":"e_1_2_1_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02087911"},{"key":"e_1_2_1_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401514"},{"key":"e_1_2_1_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70550-0"},{"key":"e_1_2_1_55_1","unstructured":"J-695 also known as ABT-874 drug report. The Investigational Drugs Database. August 2003."},{"key":"e_1_2_1_56_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.10.7.1207"},{"key":"e_1_2_1_57_1","unstructured":"LOHER F BAUER C SCHMALL K et al.:The ICE inhibitor pralnacasan reduces DSS-induced murine colitis and Thl-cell activation. Proceedings of the VIth International Symposium on Inflammatory Bowel Diseases Istanbul ( 2001)."},{"key":"e_1_2_1_58_1","unstructured":"\u2022Animal studies of this agent have shown that it can reduce colonic inflammation and TH1 cell activation. Human studies are awaited as CD is a predominantly TH1 disease and this drug should prove beneficial."},{"key":"e_1_2_1_59_1","unstructured":"LOVELL DJ BOWYER SL: Treatment of neonatal onset multisystem inflammatory disease (NOMID) with interleukin-1 receptor antagonists (Anakinra). Proceedings of the American College of Rheumatology Meeting Orlando USA (2003):A1313."},{"key":"e_1_2_1_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)70418-4"},{"key":"e_1_2_1_61_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.24015"},{"key":"e_1_2_1_62_1","doi-asserted-by":"crossref","unstructured":"YACYSHYN BR CHEY W GOFF J et al.: Double-blinded randomized placebo-controlled trial of the remission inducing and steroid sparing properties of two schedules of ISIS 2302 (ICAM-1 antisense) in active steroid-dependent Crohn's disease. Proceedings of the Digestive Disease Week San Diego USA (2000):A570.","DOI":"10.1016\/S0016-5085(00)84415-7"},{"key":"e_1_2_1_63_1","doi-asserted-by":"crossref","unstructured":"MINER PB BANE BL SADIQ SA BRADLEY JD WEDEL M: Antisense inhibitor of ICAM-1 given as enema improves symptomatic pouchitis. Proceedings of the Digestive Disease Week (2003) Orlando USA (2003) (Abstract T1395)","DOI":"10.1016\/S0016-5085(03)82656-2"},{"key":"e_1_2_1_64_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.158.5.2099"},{"key":"e_1_2_1_65_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116575"},{"key":"e_1_2_1_66_1","unstructured":"FEAGAN B GREENBERG G WILD G et al.: A randomized controlled trial of a humanized antibody in ulcerative colitis. Proceedings of the American College of Gastroenterology Annual Meeting Baltimore USA (2003) A9."},{"key":"e_1_2_1_67_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.26260"},{"key":"e_1_2_1_68_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020732"},{"key":"e_1_2_1_69_1","unstructured":"\u2022\u2022CD patients showed both response andremission of their disease at week 6 when they received two infusions of the drug. Quality-of-life scales also showed an improvement."},{"key":"e_1_2_1_70_1","unstructured":"SANDBORN W COLOMBEL JF ENNS R et al.: Results from a Phase III study on the evaluation of natalizumab in active Crohn's disease therapy-1 (ENACT-1). Proceedings of the American College of Gastroenterology Annual Meeting Baltimore USA (2003) (Abstract 55A)."},{"key":"e_1_2_1_71_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005541700805"},{"key":"e_1_2_1_72_1","doi-asserted-by":"crossref","unstructured":"KORZENIK JR DIECKGRAEFE BK: Immunostimulation in Crohn's disease: results of a pilot study of G-CSF (rhu G-CSF) in mucosal and fistulizing Crohn's disease. Proceedings of the Digestive Disease Week meeting San Diego USA (2000):A874\u2013A875.","DOI":"10.1016\/S0016-5085(00)85638-3"},{"key":"e_1_2_1_73_1","doi-asserted-by":"crossref","unstructured":"DEJACO C GASCHE C POETZI R et al.: Safety and efficacy of granulocyte colony stimulating factor (G-CSF) for treatment of severe endoscopic postoperative recurrence in Crohn's disease. Proceedings of the Digestive Disease Week San Diego USA (2000):A566.","DOI":"10.1016\/S0016-5085(00)84397-8"},{"key":"e_1_2_1_74_1","doi-asserted-by":"crossref","unstructured":"KORZENIK JR DIECKGRAEFE BK: Immune stimulation in Crohn's disease: Safety and efficacy of rhuGM-CSF for the treatment of active Crohn's disease. Proceedings of the Digestive Disease Week Atlanta USA (2001):A277\u2013A278.","DOI":"10.1016\/S0016-5085(01)81376-7"},{"key":"e_1_2_1_75_1","unstructured":"KORZENIK J DIECKGRAEFE B VALENTINE JF: Sargramostim (Leukine) induces response and remission in moderately to severely active Crohn's disease: results from the first randomized double-blind placebo-controlled trial. Proceedings of the Annual Meeting of the American College of Gastroenterology\u201e Baltimore USA (2003) 49A."},{"key":"e_1_2_1_76_1","unstructured":"\u2022This study tested the hypothesis that impaired neutrophil and\/or monocyte function is the underlying pathogenic defect in some CD patients rather than excessive T-cell response by treating patients with GM-CSF versus placebo."},{"key":"e_1_2_1_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90006-X"},{"key":"e_1_2_1_78_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.8.10.1224"},{"key":"e_1_2_1_79_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.135.2.798"},{"key":"e_1_2_1_80_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.30.18779"},{"key":"e_1_2_1_81_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI7145"},{"key":"e_1_2_1_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)00262-2"},{"key":"e_1_2_1_83_1","first-page":"2424","article-title":"Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats","volume":"61","author":"TANAKA T","year":"2001","unstructured":"TANAKA T, KOHNO H, YOSHITANI S et al.: Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res. (2001) 61:2424\u20132428.","journal-title":"Cancer Res."},{"key":"e_1_2_1_84_1","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200209000-00004"},{"key":"e_1_2_1_85_1","first-page":"827","article-title":"Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)\/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer","volume":"193","author":"DESREUMAUX P","year":"2001","unstructured":"DESREUMAUX P, DUBUQUOY L, NUTTEN S et al.: Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)\/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J. Exp. Med. (2001) 193:827\u2013838.","journal-title":"A basis for new therapeutic strategies. J. Exp. Med."},{"key":"e_1_2_1_86_1","unstructured":"\u2022Raised the possibility that a PPAR-y heterodimer may be of therapeutic benefit in colonic inflammation."},{"key":"e_1_2_1_87_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.21191"},{"key":"e_1_2_1_88_1","doi-asserted-by":"crossref","unstructured":"SUGAWARA K STEVENS BK SHASHKIN P et al.: PPARgamma: a candidate gene for ileitis in the SAMP1\/ YitFc mice model of Crohn's disease. Proceedings of the Digestive Disease Week Orlando USA (2003):A368.","DOI":"10.1016\/S0016-5085(03)81860-7"},{"key":"e_1_2_1_89_1","first-page":"1306","article-title":"Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese","volume":"86","author":"GHANIM H","year":"2001","unstructured":"GHANIM H, GARG R, ALJADA A et al.:Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. Clin. Endocrinol Metab. (2001) 86:1306\u20131312.","journal-title":"Clin. Endocrinol Metab."},{"key":"e_1_2_1_90_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1463-1326.2000.00072.x"},{"key":"e_1_2_1_91_1","doi-asserted-by":"crossref","unstructured":"HAFFNER SM GREENBERG AS WESTON WM CHEN H WILLIAMS K FREED MI: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with Type 2 diabetes mellitus. Circulation (2002) 106:679-684. ao.MARX N FROEHLICH J SIAM L et al.: Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in Type 2 diabetic patients with coronary artery disease. Arteriosclec Thromb. Vasc. Biol. (2003) 23:283\u2013288.","DOI":"10.1161\/01.CIR.0000025403.20953.23"},{"key":"e_1_2_1_92_1","doi-asserted-by":"crossref","unstructured":"SU C LEWIS JD DEREN J et al: Peroxisome proliferators-activated receptor ligand rosiglitazone for the treatment of active Crohn's disease. Proceedings of the Digestive Disease Week Orlando USA (2003):A380.","DOI":"10.1016\/S0016-5085(03)81924-8"},{"key":"e_1_2_1_93_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200006013422203"},{"issue":"3","key":"e_1_2_1_94_1","first-page":"274","article-title":"Long term results in the treatment of regional ileitis with coherin","volume":"67","author":"HIATT RB","year":"1977","unstructured":"HIATT RB, GOODMAN I: Long term results in the treatment of regional ileitis with coherin. Amj Gastroenterol (1977) 67(3):274\u2013277.","journal-title":"Amj Gastroenterol"},{"key":"e_1_2_1_95_1","doi-asserted-by":"crossref","unstructured":"LICHTENSTEIN GR JACOBY HI: Coherin peptides induce clinical response and remission in patients with active Crohn's disease. Proceedings of the American College of Gastroenterology Annual Meeting Seattle USA (2002):A763.","DOI":"10.1016\/S0002-9270(02)05246-2"},{"key":"e_1_2_1_96_1","doi-asserted-by":"crossref","unstructured":"LICHTENSTEIN GR JACOBY HI: Coherin peptides effectively maintain remission in patients with Crohn's disease for 2 years. Proceedings of the American College of Gastroenterology Annual Meeting Seattle USA (2002):A764.","DOI":"10.1016\/S0002-9270(02)05247-4"},{"key":"e_1_2_1_97_1","unstructured":"\u2022The re-use of coherin a peptide extract of bovine and porcine posterior pituitary gland that had been used several years ago has stimulated interest in this agent as an alternative treatment for CD."},{"key":"e_1_2_1_98_1","doi-asserted-by":"crossref","unstructured":"ARONCHICK C DALKE D IONNA S RIFF D SCHIFF M: Medroxyprogesterone acetate is effective in the treatment of ulcerative colitis. Proceedings of the Digestive Disease Week Atlanta USA (2001):A455.","DOI":"10.1016\/S0016-5085(08)82254-8"},{"key":"e_1_2_1_99_1","doi-asserted-by":"crossref","unstructured":"SCHREIBER AD INDIK ZK ROSE M: Medroxyprogesterone acetate a progestin and partial glucocorticoid agonist\/ antagonist with anti-inflammatory activity in IBD does not suppress the level of circulating lymphocytes. Proceedings of the American College of Gastroenterology Annual Meeting Baltimore USA (2003):A527.","DOI":"10.1111\/j.1572-0241.2003.08491.x"},{"key":"e_1_2_1_100_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01433.x"},{"key":"e_1_2_1_101_1","unstructured":"\u2022The first pilot study of the use of DHEA in CD based on the fact that some CD patients have decreased levels of DHEAS and that DHEA inhibits the activation of NF-x13."},{"key":"e_1_2_1_102_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.47.6.779"},{"key":"e_1_2_1_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(24)29668-3"},{"key":"e_1_2_1_104_1","unstructured":"RUTGEERTS P REINISCH W COLOMBEL JF et al.: Preliminary results of a Phase I\/II study of Huzaf an anti-interferon gamma monoclonal antibody in patients with moderate to severe active Crohn's disease. Proceedings of the Digestive Disease Week San Francisco USA (2002):A505."},{"key":"e_1_2_1_105_1","unstructured":"\u2022A different approach to treatment of CD as IFN-y is thought to be a key cytokine that enhances the development of a TH1 irmrtune response and also suppresses the proliferation of TH2 cells."},{"key":"e_1_2_1_106_1","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200108000-00001"},{"key":"e_1_2_1_107_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07413.x"},{"key":"e_1_2_1_108_1","unstructured":"HERRLINGER KR KREISEL W SCHWAB M et al.: Open prospective trial on 6-thioguanine for chronic active Crohn's disease. Proceedings of the Digestive Disease Week San Francisco CA USA (2002):A432."},{"key":"e_1_2_1_109_1","first-page":"A672","article-title":"Oral 6-thioguanine (TG) causes relatively mild and reversible hepatic veno-occlusive disease (VOD)","author":"STORK LC","year":"1998","unstructured":"STORK LC, ERDMARU G, ADAMSON P et al.: Oral 6-thioguanine (TG) causes relatively mild and reversible hepatic veno-occlusive disease (VOD). Proceedings of the Annual Meeting of the Hematology Oncology (Huntingt) Society (1998):A672.","journal-title":"Proceedings of the Annual Meeting of the Hematology Oncology (Huntingt) Society"},{"key":"e_1_2_1_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)00938-7"},{"key":"e_1_2_1_111_1","unstructured":"\u2022Raises awareness of NRH as a side effect of using 6-TG to treat IBD patients."},{"key":"e_1_2_1_112_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200308000-00006"},{"key":"e_1_2_1_113_1","doi-asserted-by":"crossref","unstructured":"\u2022Use of an irnmunomodulator not previously used to treat IBD helps with expanding the therapeutic armarnentariurn. oa. SANDBORN WJ PRESENT DH ISAACS KL et al.: Tacrolimus for the treatment of fistulas in patients with Crohn's disease: A randomized placebo-controlled trial. Gastroenterology (2003) 125:380\u2013388.","DOI":"10.1016\/S0016-5085(03)00877-1"},{"key":"e_1_2_1_114_1","unstructured":"RUTGEERTS P VAN ASSCHE G D'HAENS G et al.: Ornidazole for prophylaxis of postoperative Crohn's disease: Final results of a double blind placebo controlled trial. Proceedings of the Digestive Disease Week San Francisco CA USA. (2002):A80."},{"key":"e_1_2_1_115_1","unstructured":"\u2022\u2022First report of a potentially useful agent toprevent or delay post-operative recurrence of CD but patient noncompliance may be an issue secondary to drug side effects."},{"key":"e_1_2_1_116_1","doi-asserted-by":"crossref","unstructured":"SHAFRAN I JOHNSON LK HAMM L MURDOCK RH: Efficacy and tolerability of rifaximin a non-absorbed oral antibiotic in the treatment of active Crohn's disease: Results of an open-label study. Proceedings of the American College of Gastroenterology Annual Meeting Baltimore USA (2003):A281.","DOI":"10.1111\/j.1572-0241.2003.08493.x"},{"key":"e_1_2_1_117_1","unstructured":"\u2022A non-absorbable oral antibiotic that appears to be of benefit in CD though a randomised double-blind placebo-controlled trial is awaited for confirmation of this benefit and lack of side effects."},{"key":"e_1_2_1_118_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.3.377"},{"key":"e_1_2_1_119_1","unstructured":"\u2022Preliminary data on a chemotherapeutic agent that may prove to be useful in CD patients."},{"key":"e_1_2_1_120_1","first-page":"4","article-title":"Investig","volume":"13","author":"Expert Op\/n","year":"2004","unstructured":"Expert Op\/n. Investig. Drugs (2004) 13(4)","journal-title":"Drugs"},{"key":"e_1_2_1_121_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.01054.x"},{"key":"e_1_2_1_122_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000062540.29757.E9"},{"key":"e_1_2_1_123_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07660.x"},{"key":"e_1_2_1_124_1","unstructured":"\u2022Preliminary data on the use of non-disease-producing intestinal helminthes to induce a TH2 response and downregulate a chronic TH1 response which is thought to be one of the pathogenesic mechanisms of CD."}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/13543784.13.4.373","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T04:42:49Z","timestamp":1772772169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/13543784.13.4.373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":122,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["10.1517\/13543784.13.4.373"],"URL":"https:\/\/doi.org\/10.1517\/13543784.13.4.373","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,4]]}}}